The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | Selective Treg targeting for lung cancer prevention in high-risk patients
James Reading, PhD, University College London, London, UK, discusses the role of regulatory T cells in immunosuppression and their emergence in the pre-invasive phase of cancer. Dr Reading highlights the potential of targeting a specific subset of regulatory T cells with a PI3Kδ inhibitor, roginolisib, which may provide a safer and more selective approach to preventing lung cancer in high-risk patients. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
